MX2016016404A - Metodos para el tratamiento del prurito. - Google Patents
Metodos para el tratamiento del prurito.Info
- Publication number
- MX2016016404A MX2016016404A MX2016016404A MX2016016404A MX2016016404A MX 2016016404 A MX2016016404 A MX 2016016404A MX 2016016404 A MX2016016404 A MX 2016016404A MX 2016016404 A MX2016016404 A MX 2016016404A MX 2016016404 A MX2016016404 A MX 2016016404A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- pruritus
- present
- treating
- treating pruritus
- Prior art date
Links
- 208000003251 Pruritus Diseases 0.000 title abstract 3
- 239000003908 antipruritic agent Substances 0.000 abstract 3
- 150000002148 esters Chemical class 0.000 abstract 2
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 abstract 2
- 229960000805 nalbuphine Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000001139 anti-pruritic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001823 pruritic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462011936P | 2014-06-13 | 2014-06-13 | |
| PCT/US2015/035650 WO2015192071A1 (en) | 2014-06-13 | 2015-06-12 | Methods for treating pruritus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016016404A true MX2016016404A (es) | 2017-11-30 |
Family
ID=54834447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016404A MX2016016404A (es) | 2014-06-13 | 2015-06-12 | Metodos para el tratamiento del prurito. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20150359789A1 (enExample) |
| EP (1) | EP3154546A4 (enExample) |
| JP (1) | JP2017517553A (enExample) |
| KR (1) | KR20170016983A (enExample) |
| CN (1) | CN106535897A (enExample) |
| AU (1) | AU2015274327A1 (enExample) |
| BR (1) | BR112016029236A2 (enExample) |
| CA (1) | CA2951420A1 (enExample) |
| IL (1) | IL249475A0 (enExample) |
| MX (1) | MX2016016404A (enExample) |
| RU (1) | RU2017101102A (enExample) |
| WO (1) | WO2015192071A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US20170216277A1 (en) * | 2016-01-06 | 2017-08-03 | Trevi Therapeutics, Inc. | Therapeutic use of nalbuphine without aquaretic effects |
| US20180008592A1 (en) * | 2016-03-21 | 2018-01-11 | Trevi Therapeutics, Inc. | Treatment of uremic pruritus |
| AU2017350852A1 (en) * | 2016-10-25 | 2019-04-11 | Trevi Therapeutics, Inc. | Treatment of prurigo nodularis |
| MX2020009813A (es) * | 2018-03-29 | 2020-11-11 | Lumosa Therapeutics Co Ltd | Composiciones y metodos para tratar el prurito. |
| JP2021532080A (ja) * | 2018-07-11 | 2021-11-25 | トレビ セラピューティクス インコーポレイテッド | 肝疾患の掻痒症状の治療 |
| MX2021000908A (es) | 2018-07-23 | 2021-06-08 | Trevi Therapeutics Inc | Tratamiento de la tos cronica, la dificultad respiratoria y la disnea. |
| MX2022008554A (es) | 2020-01-10 | 2022-08-10 | Trevi Therapeutics Inc | Metodos de administracion de nalbufina. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1931315E (pt) * | 2005-08-24 | 2014-01-03 | Endo Pharmaceuticals Inc | Formulações de libertação sustentada de nalbufina |
| US8394812B2 (en) * | 2005-08-24 | 2013-03-12 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
| WO2008128892A1 (en) * | 2007-04-23 | 2008-10-30 | Symrise Gmbh & Co. Kg | Polyethylene glycol esters and cosmetic and/or dermatological preparations |
| US20140179727A1 (en) * | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| KR20220044385A (ko) * | 2012-12-14 | 2022-04-07 | 트레비 테라퓨틱스, 인코포레이티드 | 소양증을 치료하는 방법 |
| US8637538B1 (en) * | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| US8987289B2 (en) * | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
-
2015
- 2015-06-12 WO PCT/US2015/035650 patent/WO2015192071A1/en not_active Ceased
- 2015-06-12 EP EP15807379.1A patent/EP3154546A4/en not_active Withdrawn
- 2015-06-12 RU RU2017101102A patent/RU2017101102A/ru not_active Application Discontinuation
- 2015-06-12 BR BR112016029236A patent/BR112016029236A2/pt not_active Application Discontinuation
- 2015-06-12 KR KR1020177001115A patent/KR20170016983A/ko not_active Withdrawn
- 2015-06-12 US US14/738,550 patent/US20150359789A1/en not_active Abandoned
- 2015-06-12 CA CA2951420A patent/CA2951420A1/en not_active Abandoned
- 2015-06-12 CN CN201580039250.9A patent/CN106535897A/zh active Pending
- 2015-06-12 AU AU2015274327A patent/AU2015274327A1/en not_active Abandoned
- 2015-06-12 MX MX2016016404A patent/MX2016016404A/es unknown
- 2015-06-12 JP JP2016572657A patent/JP2017517553A/ja active Pending
-
2016
- 2016-12-11 IL IL249475A patent/IL249475A0/en unknown
-
2018
- 2018-04-30 US US15/966,850 patent/US20190099416A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3154546A4 (en) | 2018-01-10 |
| US20190099416A1 (en) | 2019-04-04 |
| KR20170016983A (ko) | 2017-02-14 |
| IL249475A0 (en) | 2017-02-28 |
| US20150359789A1 (en) | 2015-12-17 |
| WO2015192071A1 (en) | 2015-12-17 |
| JP2017517553A (ja) | 2017-06-29 |
| CN106535897A (zh) | 2017-03-22 |
| RU2017101102A3 (enExample) | 2019-01-28 |
| AU2015274327A1 (en) | 2017-01-05 |
| RU2017101102A (ru) | 2018-07-16 |
| BR112016029236A2 (pt) | 2017-11-07 |
| CA2951420A1 (en) | 2015-12-17 |
| EP3154546A1 (en) | 2017-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016016404A (es) | Metodos para el tratamiento del prurito. | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| PH12017500941A1 (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| MY192717A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| PH12015502075B1 (en) | Treatment of cataplexy | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| MX2017000980A (es) | Composiciones de tratamiento. | |
| MX2017000976A (es) | Composiciones de tratamiento. | |
| EA201891347A1 (ru) | Аза-бензимидазольные ингибиторы pad4 | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX2018002718A (es) | Composiciones que comprenden quelante acido para tratar formaciones subterraneas que incluyan una o mas fracturas. | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| EA201890810A1 (ru) | Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение | |
| MX2015012741A (es) | Palbociclib deuterado. | |
| MX2016014559A (es) | Compuestos para el tratamiento de cancer. | |
| WO2016069477A3 (en) | A method of treating cancer that overexpresses topbp1 | |
| EA201791363A1 (ru) | Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2 | |
| MA39824A (fr) | Composés azole amido-substitués | |
| MX2018005004A (es) | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. | |
| EA201591434A1 (ru) | Способ обеспечения глазной нейропротекции | |
| MX2017004819A (es) | Metodos de tratamiento de transtornos urológicos usando sarm. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| MX2019004804A (es) | Tratamiento para el prurigo nodula. |